Literature DB >> 34446472

Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study.

Hannah Oh1,2, Robert A Wild3, JoAnn E Manson4, Jennifer W Bea5, Aladdin H Shadyab6, Ruth M Pfeiffer7, Nazmus Saquib8, Lisa Underland9, Garnet L Anderson10, Xia Xu11, Britton Trabert7.   

Abstract

BACKGROUND: Anthropometric measures, including obesity, are important risk factors for breast and endometrial cancers in postmenopausal women. It is unknown whether these risk factors are associated with androgen metabolism, another risk factor for these cancers.
METHODS: Using baseline data from 1,765 postmenopausal women in the Women's Health Initiative Observational Study, we conducted a cross-sectional analysis examining associations between anthropometric measures [current body mass index (BMI), waist-to-hip ratio (WHR), height, and recalled BMI at age 18) and serum androgen metabolites. Twelve androgens/androgen metabolites were quantified using LC-MS/MS. Geometric means of androgen/androgen metabolite concentrations were estimated using linear regression, adjusting for potential confounders and stratified by hormone therapy (HT) use.
RESULTS: Regardless of HT use, higher current BMI (≥30 vs. <25 kg/m2) was associated with higher serum concentrations of dehydroepiandrosterone sulfate (DHEAS), 5α-reduced glucuronide metabolites [androsterone-glucuronide (ADT-G), 5α-androstane-3α,17β diol-3-glucuronide (3α-diol-3G), 3α-diol-17-glucuronide (3α-diol-17G)], and DHEAS:DHEA ratio (all P trend ≤ 0.02). BMI was also positively associated with unconjugated estrone:androstenedione and unconjugated estradiol:testosterone ratios among never/former HT users (all P trend < 0.001) but not among current users (P-int < 0.001). WHR was positively associated with adrenal androgens and 5α-reduced glucuronide metabolites in obese women only (BMI ≥ 30 kg/m2; all P-trend ≤ 0.01). BMI at age 18 was inversely associated with adrenal androgens (DHEA, DHEAS, androstenedione, testosterone) and 5α-reduced glucuronide metabolites in never/former HT users (all P trend < 0.06). Height was not associated with androgen metabolites.
CONCLUSIONS: Current BMI is associated with androgen metabolism among postmenopausal women. IMPACT: This study contributes to our understanding of the link between obesity and cancer risk in postmenopausal women. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34446472      PMCID: PMC8568664          DOI: 10.1158/1055-9965.EPI-21-0604

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  53 in total

1.  Circulating steroid hormone levels and risk of breast cancer for postmenopausal women.

Authors:  Laura Baglietto; Gianluca Severi; Dallas R English; Kavitha Krishnan; John L Hopper; Catriona McLean; Howard A Morris; Wayne D Tilley; Graham G Giles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

Review 2.  Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies.

Authors:  D Aune; D A Navarro Rosenblatt; D S M Chan; S Vingeliene; L Abar; A R Vieira; D C Greenwood; E V Bandera; T Norat
Journal:  Ann Oncol       Date:  2015-03-19       Impact factor: 32.976

3.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

4.  Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women.

Authors:  Louise A Brinton; Britton Trabert; Garnet L Anderson; Roni T Falk; Ashley S Felix; Barbara J Fuhrman; Margery L Gass; Lewis H Kuller; Ruth M Pfeiffer; Thomas E Rohan; Howard D Strickler; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-12       Impact factor: 4.254

5.  The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures.

Authors:  Robert D Langer; Emily White; Cora E Lewis; Jane M Kotchen; Susan L Hendrix; Maurizio Trevisan
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

6.  Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women.

Authors:  A Lukanova; E Lundin; A Zeleniuch-Jacquotte; P Muti; A Mure; S Rinaldi; L Dossus; A Micheli; A Arslan; P Lenner; R E Shore; V Krogh; K L Koenig; E Riboli; F Berrino; G Hallmans; P Stattin; P Toniolo; R Kaaks
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

7.  Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort.

Authors:  Sabina Sieri; Vittorio Krogh; Gianfranco Bolelli; Carlo Alberto Abagnato; Sara Grioni; Valeria Pala; Alberto Evangelista; Claudia Allemani; Andrea Micheli; Giovanna Tagliabue; Holger J Schunemann; Sylvie Menard; Franco Berrino; Paola Muti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

8.  Intracrinology in action: importance of extragonadal sex steroid biosynthesis and inactivation in peripheral tissues in both women and men.

Authors:  Fernand Labrie
Journal:  J Steroid Biochem Mol Biol       Date:  2014-09-18       Impact factor: 4.292

9.  Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry.

Authors:  Xia Xu; John M Roman; Haleem J Issaq; Larry K Keefer; Timothy D Veenstra; Regina G Ziegler
Journal:  Anal Chem       Date:  2007-09-12       Impact factor: 6.986

10.  Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC).

Authors:  John L Hopper; Gillian S Dite; Robert J MacInnis; Yuyan Liao; Nur Zeinomar; Julia A Knight; Melissa C Southey; Roger L Milne; Wendy K Chung; Graham G Giles; Jeanine M Genkinger; Sue-Anne McLachlan; Michael L Friedlander; Antonis C Antoniou; Prue C Weideman; Gord Glendon; Stephanie Nesci; Irene L Andrulis; Saundra S Buys; Mary B Daly; Esther M John; Kelly Anne Phillips; Mary Beth Terry
Journal:  Breast Cancer Res       Date:  2018-11-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.